Scientists from the University of St Andrews reveal a new tuberculosis (TB) therapeutics that could shorten the treatment of the disease by up to two months, potentially saving millions of lives. Dr. Muge Cevik delivered the results of the worldwide TB Alliance's SimpliciTB clinical trial at the 30th annual Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle on Monday, February 20. Tuberculosis causes about 1 million deaths every year. To change this and save lives, new tools and new treatments are required. Active TB must be treated with a combination of drugs; the most drug-sensitive forms of TB require...